We are live on ! Find out more
CDAK

Codiak BioSciences, Inc. Common Stock

Delisted

CDAK was delisted on the 4th of April, 2023.

48 hedge funds and large institutions have $13.6M invested in Codiak BioSciences, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 12

2% less funds holding

Funds holding: 4948 (-1)

14% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 14

60% less capital invested

Capital invested by funds: $33.9M → $13.6M (-$20.3M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
48
Holders Change
-1
Holders Change %
-2.04%
% of All Funds
0.82%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
11
Increased
12
Reduced
14
Closed
12
Calls
$10K
Puts
Net Calls
+$10K
Net Calls Change
-$9K

CDAK Hedge Fund Activity: Q3 2022 in Review

48 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Codiak BioSciences, Inc. Common Stock (CDAK) for Q3 2022, worth a combined $13.6M — down 60% from $33.9M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of CDAK and 11 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 12 added.

The largest buyer was Laurion Capital Management, adding an estimated $3.57M. The largest seller was Oracle Investment Management, exiting entirely with an estimated $1.34M sold.

  • 48 institutional investors held Codiak BioSciences, Inc. Common Stock (CDAK) as of Q3 2022, down from 49 in Q2 2022.
  • Funds reported $13.6M of Codiak BioSciences, Inc. Common Stock stock for Q3 2022, down 60% quarter-over-quarter.
  • 11 funds opened new Codiak BioSciences, Inc. Common Stock positions in Q3 2022 and 12 closed out, a net change of -1 holder.
  • The largest Codiak BioSciences, Inc. Common Stock buyer in Q3 2022 was Laurion Capital Management, an estimated $3.57M added.
  • The largest Codiak BioSciences, Inc. Common Stock seller in Q3 2022 was Oracle Investment Management, an estimated $1.34M sold.

Based on aggregated 13F filings for Q3 2022.